Real-World Treatment Patterns and Clinical Outcomes of BRAF V600-Mutant Metastatic Melanoma Patients Treated at Academic Oncology Centers in the United States

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/1000000307
• EU PAS number:
  EUPAS1000000307
• Study ID:
  1000000307
• Official title and acronym:
  Real-World Treatment Patterns and Clinical Outcomes of BRAF V600-Mutant Metastatic Melanoma Patients Treated at Academic Oncology Centers in the United States
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  The overarching aim of this study is to describe the real-world characteristics, treatment patterns, and clinical outcomes of patients with BRAF V600-mutant MM presenting for care at academic oncology centers in the US from January 1, 2018 to June 30, 2024 (or the most recent date of data availability.
• Study status:
  Planned

Research institutions and networks

Institutions

Pfizer

Study timelines

Date when funding contract was signed

Actual: 04/04/2023

Study start date

Planned: 18/11/2024

Data analysis start date

Planned: 06/12/2024

Date of final study report

Planned: 20/06/2025

Sources of funding

Pharmaceutical company and other private sector 

Study protocol

Initial protocol

C4221039_RW Treatment Patterns and Clinical Outcomes in BRAF+ MM_Study Protocol_V1.0_17Oct2024_REDACTED.pdf

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable